Madrigal Pharmaceuticals to Participate in the 2026 Cantor Global Healthcare Conference
Madrigal Pharmaceuticals (MDGL) will participate in the 2026 Cantor Global Healthcare Conference on Thursday, September 10, 2026 at 1:00 p.m. EDT.
Rhea-AI Summary
Madrigal Pharmaceuticals (MDGL) will participate in the 2026 Cantor Global Healthcare Conference on Thursday, September 10, 2026 at 1:00 p.m. EDT. The company’s presentation will be webcast live and accessible via Madrigal’s Investor Relations Events and Presentations page, with a replay available after the event.
Positive
- None.
Negative
- None.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Aug 20 | Inducement awards | Neutral | -0.5% | Employee equity awards were followed by a modest negative price reaction. |
| Aug 12 | Board appointment | Positive | +0.2% | Appointment of an experienced biopharmaceutical executive was followed by a modest gain. |
| Aug 06 | Inducement awards | Neutral | -0.1% | Employee equity awards were followed by a nearly unchanged negative reaction. |
| Aug 06 | Conference participation | Neutral | -0.7% | A conference participation announcement was followed by a negative price reaction. |
| Jul 30 | 2Q26 earnings report | Negative | -9.8% | Quarterly results and corporate updates were followed by a sharp negative price reaction. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent reactions were mixed: the prior earnings release aligned with a sharp decline, while a board appointment produced a modest gain.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CONSHOHOCKEN, Pa., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that the company will participate in the 2026 Cantor Global Healthcare Conference on Thursday, Sept. 10, 2026 at 1:00 P.M. EDT.
The presentation will be webcast live and may be accessed here or by visiting Madrigal’s Investor Relations Events and Presentations page. A replay of the webcast will be available after the event.
About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra was the first medication approved by both the FDA and European Commission for the treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c). For more information, visit www.madrigalpharma.com.
Investor Contact
Tina Ventura, IR@madrigalpharma.com
Media Contact
Christopher Frates, media@madrigalpharma.com
